Publicaciones en colaboración con investigadores/as de Uppsala University (18)

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  3. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Deciphering conformational selectivity in the A2A adenosine G protein-coupled receptor by free energy simulations

    PLoS Computational Biology, Vol. 17, Núm. 11

  3. Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition

    Scientific Reports, Vol. 11, Núm. 1

  4. Potent and Subtype-Selective Dopamine D2Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach

    Journal of Medicinal Chemistry, Vol. 64, Núm. 12, pp. 8710-8726

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

  2. The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling

    ACS Pharmacology and Translational Science, Vol. 3, Núm. 2, pp. 361-370

2019

  1. Free-Energy calculations for bioisosteric modifications of A3adenosine receptor antagonists

    International Journal of Molecular Sciences, Vol. 20, Núm. 14

  2. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330

2017

  1. 3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation

    ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933

  2. Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists

    Journal of Medicinal Chemistry, Vol. 60, Núm. 17, pp. 7502-7511

  3. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

2016

  1. Combining ligand-based and structure-based ligand design towards the development of potent and selective antagonists for the adenosine receptors

    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

  2. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes

    Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1967-1983

2012

  1. Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: Implications for the charge state of the protein ionogenic groups

    Bioorganic and Medicinal Chemistry, Vol. 20, Núm. 15, pp. 4838-4847

2010

  1. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1

    Biochemistry, Vol. 49, Núm. 34, pp. 7255-7263